A randomised, double-blind, placebo-controlled ascending dose tolerability and safety study of remacemide as adjuvant therapy in Parkinson's disease with response fluctuations

Carl Clarke, JA Cooper, TAH Holdich

    Research output: Contribution to journalArticle

    22 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)133-138
    Number of pages6
    JournalClinical Neuropharmacology
    Publication statusPublished - 1 May 2001

    Cite this